HK Stock Movement | ESSEX BIO-TECH (01061) Rises Nearly 9% in Afternoon Session; Company to Showcase Multiple Core Ophthalmology Products at APAO 2026

Stock News

Jan 27

ESSEX BIO-TECH (01061) rose nearly 9% in the afternoon session. As of the time of writing, the stock was up 5.83%, trading at HK$4.36, with a turnover of HK$5.2576 million. The company recently announced that the Group will exhibit at the 2026 Asia-Pacific Academy of Ophthalmology Congress (APAO 2026), held from February 5th to 8th at the Hong Kong Convention and Exhibition Centre. The Group will prominently feature two core products: EB12-20145P (Bevacizumab) and single-dose Befushu Eye Drops. Notably, EB12-20145P continues to demonstrate strong momentum in clinical development. This project has been selected for the congress's poster presentation session, where its clinical progress and R&D insights will be showcased to the international ophthalmology community. It is also worth noting that the company recently announced that its wholly-owned subsidiary, Majeton, has entered into an exclusive distribution agreement with Osteopore. Osteopore is a global leader in 3D printed bio-mimetic and bio-resorbable implants. The collaboration with Osteopore marks a milestone for the Group in the dental market, expanding its portfolio of dental, orthodontic, and maxillofacial solutions, and is set to jointly support the Group's pursuit of sustainable growth in the Chinese market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1126880189"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126880189\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126880189?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-27 14:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126880189","market":"sg","top_or_hot":-1,"title":"HK Stock Movement | ESSEX BIO-TECH (01061) Rises Nearly 9% in Afternoon Session; Company to Showcase Multiple Core Ophthalmology Products at APAO 2026","media":"Stock News","content":"<p>ESSEX BIO-TECH (01061) rose nearly 9% in the afternoon session. As of the time of writing, the stock was up 5.83%, trading at HK$4.36, with a turnover of HK$5.2576 million.\nThe company recently announced that the Group will exhibit at the 2026 Asia-Pacific Academy of Ophthalmology Congress (APAO 2026), held from February 5th to 8th at the Hong Kong Convention and Exhibition Centre.\nThe Group will prominently feature two core products: EB12-20145P (Bevacizumab) and single-dose Befushu Eye Drops.\nNotably, EB12-20145P continues to demonstrate strong momentum in clinical development.\nThis project has been selected for the congress's poster presentation session, where its clinical progress and R&D insights will be showcased to the international ophthalmology community.\nIt is also worth noting that the company recently announced that its wholly-owned subsidiary, Majeton, has entered into an exclusive distribution agreement with Osteopore.\nOsteopore is a global leader in 3D printed bio-mimetic and bio-resorbable implants.\nThe collaboration with Osteopore marks a milestone for the Group in the dental market, expanding its portfolio of dental, orthodontic, and maxillofacial solutions, and is set to jointly support the Group's pursuit of sustainable growth in the Chinese market.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | ESSEX BIO-TECH (01061) Rises Nearly 9% in Afternoon Session; Company to Showcase Multiple Core Ophthalmology Products at APAO 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | ESSEX BIO-TECH (01061) Rises Nearly 9% in Afternoon Session; Company to Showcase Multiple Core Ophthalmology Products at APAO 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-27 14:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ESSEX BIO-TECH (01061) rose nearly 9% in the afternoon session. As of the time of writing, the stock was up 5.83%, trading at HK$4.36, with a turnover of HK$5.2576 million.\nThe company recently announced that the Group will exhibit at the 2026 Asia-Pacific Academy of Ophthalmology Congress (APAO 2026), held from February 5th to 8th at the Hong Kong Convention and Exhibition Centre.\nThe Group will prominently feature two core products: EB12-20145P (Bevacizumab) and single-dose Befushu Eye Drops.\nNotably, EB12-20145P continues to demonstrate strong momentum in clinical development.\nThis project has been selected for the congress's poster presentation session, where its clinical progress and R&D insights will be showcased to the international ophthalmology community.\nIt is also worth noting that the company recently announced that its wholly-owned subsidiary, Majeton, has entered into an exclusive distribution agreement with Osteopore.\nOsteopore is a global leader in 3D printed bio-mimetic and bio-resorbable implants.\nThe collaboration with Osteopore marks a milestone for the Group in the dental market, expanding its portfolio of dental, orthodontic, and maxillofacial solutions, and is set to jointly support the Group's pursuit of sustainable growth in the Chinese market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1126880189","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126880189","pubTimestamp":1769496262,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ESSEX BIO-TECH (01061) rose nearly 9% in the afternoon session. As of the time of writing, the stock was up 5.83%, trading at HK$4.36, with a turnover of HK$5.2576 million. The company recently...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","01061":"亿胜生物科技"},"translate_title":"港股动向|亿胜生物(01061)午后涨近9%；公司将在APAO 2026上展示多款核心眼科产品","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01061":1},"content_text":"ESSEX BIO-TECH (01061) rose nearly 9% in the afternoon session. As of the time of writing, the stock was up 5.83%, trading at HK$4.36, with a turnover of HK$5.2576 million.\nThe company recently announced that the Group will exhibit at the 2026 Asia-Pacific Academy of Ophthalmology Congress (APAO 2026), held from February 5th to 8th at the Hong Kong Convention and Exhibition Centre.\nThe Group will prominently feature two core products: EB12-20145P (Bevacizumab) and single-dose Befushu Eye Drops.\nNotably, EB12-20145P continues to demonstrate strong momentum in clinical development.\nThis project has been selected for the congress's poster presentation session, where its clinical progress and R&D insights will be showcased to the international ophthalmology community.\nIt is also worth noting that the company recently announced that its wholly-owned subsidiary, Majeton, has entered into an exclusive distribution agreement with Osteopore.\nOsteopore is a global leader in 3D printed bio-mimetic and bio-resorbable implants.\nThe collaboration with Osteopore marks a milestone for the Group in the dental market, expanding its portfolio of dental, orthodontic, and maxillofacial solutions, and is set to jointly support the Group's pursuit of sustainable growth in the Chinese market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}